CXCL13 and renal cell carcinoma: Interestingly, significantly higher PD-L1 and CXCL13 expression was found in 30 RCC samples with MTAP/CDKN2AMUT compared with 88 patients in the MTAP/CDKN2AWT group (P < 0.01; Figures 5D, E).